Health Care/Hospital

Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGagerTM TCEs and Synthetic Lethality

SHANGHAI and HONG KONG, March 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...

2025-03-26 16:28 2965

Gene Solutions Leads the Way in Cancer Early Detection with Asia's First Clinical Validated Multi-Cancer Blood Test

SINGAPORE, March 26, 2025 /PRNewswire/ -- Gene Solutions , a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. The company's innovative SPOT-MAS test has become the first multi-cancer screening blood test inAsia...

2025-03-26 13:00 30938

Singapore's Best Workplaces in Healthcare & Biopharma™ 2025 Announced, Showcasing Insights from Nearly 10,000 Employees

SINGAPORE, March 26, 2025 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, has officially announcedSingapore's Best Workplaces in Healthcare & Biopharma™ 2025 list, celebrating 10 pioneering healthcare and biopharma companies that have created exceptional workplace...

2025-03-26 12:00 2989

Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights

SUZHOU, China, March 26, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2024 and highlighted recent business progress. Financial Summary * For the year ended December 31, 2024, we recorded total revenue of RMB 640.08...

2025-03-26 11:08 2686

Science! SDU Researchers Identified the Membrane Receptor for Ceramide in Adipocytes

JINAN, China, March 26, 2025 /PRNewswire/ -- Recently, Professor Sun Jinpeng's team atShandong University and collaborators published a research paper titled "Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis" in Science. This study employed high-throughp...

2025-03-26 11:06 2091

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

SHANGHAI, March 26, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for ...

2025-03-26 11:03 15972

Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-00...

2025-03-26 10:45 2326

Alma introduces Alma Harmony, a state-of-the-art aesthetic platform for next-level in-office treatments

Featuring a simply intelligence interface and substantial technological upgrades, the new multiplatform presents a new era in patient personalization CAESAREA, Israel, March 26, 2025 /PRNewswire/ -- Alma Lasers , a Sisram Medical company and a global leader in energy-bas...

2025-03-26 07:29 2665

Kolmar Korea Develops World's First Hybrid Composite Sunscreen, Leading the Global Suncare Market

SEOUL, South Korea, March 25, 2025 /PRNewswire/ -- Global Cosmetics ODM (Original Development Manufacturer) Kolmar Korea has achieved a groundbreaking milestone by developing the world's first hybrid composite sunscreen stabilization technology. This innovation seamlessly integrates the great UV ...

2025-03-25 21:00 3930

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

MANILA, Philippines, March 25, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation, Inc. (HFI) and the Municipality of Malinao to launch a comprehensive initiative to improve nutrition ...

2025-03-25 20:12 2437

3Shape Unveils Revolutionary TRIOS 6 Intraoral Scanner and TRIOS Dx Plus Diagnostic Software at IDS

COPENHAGEN, Denmark, March 25, 2025 /PRNewswire/ -- 3Shape today proudly introduces its revolutionary TRIOS 6 intraoral scanner, Diagnostic software - TRIOS Dx Plus*, and the DentalHealth patient app. The new TRIOS 6 intraoral scanner not only incorporates several new upgrades, including hypersp...

2025-03-25 18:51 2358

Rare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar disorder

Scientists at deCODE genetics, a subsidiary of Amgen, reveal today in Nature Genetics associations between rare loss-of-function variants in two genes and bipolar disorder. REYKJAVIK, Iceland, March 25, 2025 /PRNewswire/ -- Bipolar disorder is characterized by extreme mood swings, bouts of mania...

2025-03-25 18:00 3374

meerecompany enhances Korea-Vietnam medical exchange with Revo-i fellowship program

- Launch of SSC program to provide advanced robotic surgery training in Korea - Dr. Cao from Viet Tiep Friendship Hospital in Vietnam completed training at Severance Hospital SEOUL, South Korea, March 25, 2025 /PRNewswire/ -- meerecompany (CEO: Joon Koo Kim) announced today that its Revo-i surgi...

2025-03-25 10:00 2649

Exceptional Performance for Ureteral Stents: ICP DAS-BMP Reveals Latest TPU Materials at CMEF 2025

HSINCHU, March 25, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a committedTaiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to announce its participation in CMEF (China International Medical Equipment Fair), held fromApril 8-11, 2025,...

2025-03-25 09:45 5509

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...

2025-03-24 23:09 4301

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...

2025-03-24 22:54 4050

Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120

Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical research FREMONT, Calif., March 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announc...

2025-03-24 21:11 2868

NX Taiwan Receives Occupational Health and Safety Management System Certification

- Maintaining Safe, Healthy and Competitive Work Environment Top Priority - TOKYO, March 24, 2025 /PRNewswire/ -- Nippon Express (Taiwan) Co., Ltd. (hereafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., acquired ISO 45001:2018 certification for its occupational health and safe...

2025-03-24 16:00 2317

English Version of "Long-term Care Tech Portal" Newly Launched, Introducing Latest Care and Age Tech in Japan

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the "Long-term Care Tech Portal" (https://robotcare.jp/en/home/index?type=pw ), a portal site providing information on state-of...

2025-03-24 15:00 2786

GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

* Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib * Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will discontinue treatment due to ...

2025-03-24 10:00 2419
1 ... 124125126127128129130 ... 540